Tissue Regenix taps wound care rival KCI for latest US team member
This article was originally published in Clinica
York, UK-based regenerative medicine specialist Tissue Regenix has appointed Tim Buechner vice-president of operations for its new US subsidiary. Mr Buechner joins from advanced wound care firm KCI, where he was senior director of commercial and sales operations. His 25-year career stretches across different disciplines including contracting, revenue cycle, sales operations, finance and project management. He will work with Greg Bila, president of Tissue Regenix’s US subsidiary in San Antonio, Texas, to expand the company’s activities on that side of the Atlantic. Tissue Regenix has developed the dCell decellularization process that removes DNA and other cellular material from animal and human tissue. The remaining acellular tissue scaffold can be used to repair diseased or worn out body parts. In addition to wound care, the company is focusing on cardiac, vascular and orthopedic applications of its technology.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.